Biomarkers of response to VEGF pathway-targeted therapy discovered for renal cell carcinoma

September 13, 2006

CHICAGO -- Angiogenesis inhibitors can be far more effective in treating metastatic clear cell renal cell cancer (RCC) - an aggressive form of the most common kind of kidney cancer that is also rich in blood supply - than traditional treatments, according to accumulating evidence. They can prolong life in about a third of patients, but researchers have not been able to identify the responding patients, prior to treatment.

Now, a research team from the University of California, San Francisco (UCSF) and the Cleveland Clinic, has found that patients whose tumors produce greater amounts of vascular endothelial growth factor (VEGF) and its receptor benefit most from these targeted treatments, because these proteins are the "targets" they are designed to go after.

"The more VEGF and VEGF receptor a patient's tumor has, the better these treatments seem to work," said the study's lead author, Erich B. Jaeger, Ph.D., a postdoctoral researcher at the UCSF Comprehensive Cancer Center. "This is very exciting because, if validated, a fairly simple test could help oncologists direct these new treatments to patients who can benefit most from them."

Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

Clear cells RCCs often accumulate VEGF and other angiogenesis-related proteins due to mutation in the Von Hippel-Lindau (VHL) tumor suppressor gene. This gene was identified as the cause of the rare and inherited Von Hippel-Lindau disease, which is characterized by frequent development of clear cell renal tumors.

About half of non-inherited clear cell renal cell cancer is believed to result from mutations in the VHL gene, Jaeger said. The mutations prevent proper degradation of specific VHL target proteins, which leads to over-expression of VEGF and other proteins associated with angiogenesis, he said. These proteins cause the tumor to become highly vascular, establishing a solid blood supply to feed the cancer. When functioning normally, VHL helps regulate the production of those proteins that might otherwise contribute to tumorigenesis.

But not all VHL mutations are alike, Jaeger says. Some cause substantial changes in the protein it encodes, leading to accumulation of VEGF, and others cause less functional difference.

In this study, the research team examined 43 tumor samples taken before patients were slated to receive angiogenesis inhibitors, and they found that 25 contained VHL mutations. Of these, 15 had mutations that led to severe disruption of the normal structure of the VHL protein.

They then correlated response to the drug with the level of VEGF and its receptor in the samples, and found that "patients who had the highest levels of expression of VEGF receptor had the best response to therapy," Jaeger said. These patients experienced nearly a doubling in time to progression, gaining about six months, he said. "Because high levels of these proteins help drive the growth of tumors, it makes sense that if they are targeted and eliminated, the tumors don't progress as fast."

The researchers are preparing to test their mutational analyses on a set of renal tumor samples taken from 700 patients who were treated with Avastin, an angiogenesis inhibitor initially approved to treat advanced colon cancer. They also plan to improve the test by adding certain common mutations involving tumor suppressor genes, and the ability to look for these same mutations in paraffin-embedded tumors, which is how most samples are now prepared.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 24,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 60 other countries.

AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants.

The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care.

AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication, CR, is a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.

American Association for Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to